Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Germie van den Dobbelsteen

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
FEMS Immunology and Medical Microbiology|October 17, 2002
Neisseria meningitidis serogroup B: laboratory correlates of protectionClementien Vermont, Germie van den Dobbelsteen
Human Vaccines|April 5, 2008
Meningococcal B vaccine development and evaluation of efficacyLoek van Alphen, Germie van den Dobbelsteen
Human Vaccines|July 26, 2011
Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutantsPeter van der Ley, Germie van den Dobbelsteen
Vaccine|November 22, 2005
Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccineThomas Luijkx, Harry van Dijken, Cécile van Els, et al.
Vaccines|January 28, 2026
The Bacterial Swiss Army Knife: ExPEC Utilizes Multiple Resistance Mechanisms to Counteract Host Immune ResponsesEveline Weerdenburg, Susan King, Joyce Lübbers, et al.
Vaccine|March 23, 2005
Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school childrenJamie Findlow, Ann Lowe, Sarah Deane, et al.
Infection and Immunity|June 24, 2003
Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccineElisabeth Wedege, Betsy Kuipers, Karin Bolstad, et al.
Pathogens (Basel, Switzerland)|April 28, 2023
Colonization with <i>Escherichia coli</i> ST131-<i>H</i>30R (<i>H</i>30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to <i>H</i>30RBrian D Johnston, Connie Clabots, Tricia Bender, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|September 7, 2024
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 studyMiwa Haranaka, Atsushi Momose, Yoshikazu Nakayama, et al.
Infection and Immunity|October 24, 2003
Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation formThomas A Luijkx, Harry van Dijken, Hendrik-Jan Hamstra, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
FEMS Immunology and Medical Microbiology|October 17, 2002
Neisseria meningitidis serogroup B: laboratory correlates of protectionClementien Vermont, Germie van den Dobbelsteen
Human Vaccines|April 5, 2008
Meningococcal B vaccine development and evaluation of efficacyLoek van Alphen, Germie van den Dobbelsteen
Human Vaccines|July 26, 2011
Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutantsPeter van der Ley, Germie van den Dobbelsteen
Vaccine|November 22, 2005
Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccineThomas Luijkx, Harry van Dijken, Cécile van Els, et al.
Vaccines|January 28, 2026
The Bacterial Swiss Army Knife: ExPEC Utilizes Multiple Resistance Mechanisms to Counteract Host Immune ResponsesEveline Weerdenburg, Susan King, Joyce Lübbers, et al.
Vaccine|March 23, 2005
Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school childrenJamie Findlow, Ann Lowe, Sarah Deane, et al.
Infection and Immunity|June 24, 2003
Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccineElisabeth Wedege, Betsy Kuipers, Karin Bolstad, et al.
Pathogens (Basel, Switzerland)|April 28, 2023
Colonization with <i>Escherichia coli</i> ST131-<i>H</i>30R (<i>H</i>30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to <i>H</i>30RBrian D Johnston, Connie Clabots, Tricia Bender, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|September 7, 2024
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 studyMiwa Haranaka, Atsushi Momose, Yoshikazu Nakayama, et al.
Infection and Immunity|October 24, 2003
Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation formThomas A Luijkx, Harry van Dijken, Hendrik-Jan Hamstra, et al.
Pageof 3